Matthew S. Davids, MD, MMSc

Matthew S. Davids, MD, MMSc, is an attending physician and the director of clinical research in the Division of Lymphoma at Dana-Farber Cancer Institute, where he also serves as the associate director of the Center for Chronic Lymphocytic Leukemia. Dr Davids is an associate professor of medicine at Harvard Medical School, and he attends on the inpatient hematologic malignancies service at Brigham and Women’s Hospital. After obtaining an AB in chemistry at Harvard College, he completed his MD at Yale School of Medicine. He served as an intern, a resident, and the assistant chief resident in internal medicine at NewYork-Presbyterian/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center in New York, NY. He then completed his fellowship in hematology and oncology at Dana-Farber/Partners CancerCare and an MMSc at Harvard Medical School. 

Dr Davids has an active translational research program in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. He is focusing on studying apoptosis (in particular, Bcl-2 biology) in his laboratory and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has centered on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B-cell receptor pathway kinases, and other novel agents, as well as utilizing checkpoint blockade to enhance antitumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.